Overview
HCG is an Omnicom Group partner that helps pharmaceutical and biotech companies spread medical science and speed up the real-world impact of new medicines. It works at the crossroads of people, purpose, science, and technology to shape how information about therapies is shared with healthcare professionals and patients. Its services include medical communications, strategy, creative, and digital campaigns designed to translate complex research into clear, compliant messaging across multiple channels, ensuring the right information reaches the right audiences. What sets HCG apart is its deep focus on connecting science to real-world outcomes within the wide Omnicom network, using data-driven and multichannel approaches to coordinate across disciplines and platforms. The company’s goal is to move medicine closer to patients by accelerating the impact of science and helping pharma realize the promise of innovative medicines.
Work here?Claim your company
Simplify's Take
What believers are saying
- HCG’s parent won Novo Nordisk’s U.S. media business in August 2026.
- Healthcare Global’s 2026 management push shows leadership investing in growth execution.
- Omnicom doubled 2026 synergy targets, creating budget for HCG cross-sell and expansion.
What critics are saying
- Omnicom’s 2025-2026 restructuring cuts over 4,000 jobs and retires brands.
- Novo Nordisk’s U.S. media switch to Omnicom raises client concentration pressure across health teams.
- If Omnicom centralizes health capabilities, HCG gets absorbed into a thinner, commoditized platform.
What makes HCG unique
- Omnicom Health named Nina Hinchcliffe Global CEO in April 2025.
- HCG spans medical communications, scientific services, patient engagement, and managed markets globally.
- Omnicom’s 2026 SXSW health platform reinforces HCG’s access to fresh category insights.
Help us improve and share your feedback! Did you find this helpful?